Do we really understand what we want or need out of antimicrobial stewardship programs?

Clinical Practice

Volumn 10, Issue 1, 2013, Pages 5-9

  Herath, Chaturika ^a   Blondeau, Joseph M ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COST CONTROL; DRUG COST; DRUG SAFETY; HEALTH CARE COST; HUMAN; INFECTION CONTROL; KLEBSIELLA INFECTION; MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; MORBIDITY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT RESPONSE;

EID: 84871540113     PISSN: 20449038     EISSN: 20449046     Source Type: Journal    
DOI: 10.2217/cpr.12.81     Document Type: Review

References (20)

1. Dellit TH, Owens RC, McGowan JE et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis 44, 159-177 (2007). (Pubitemid 46084814)
2. Lawton RM, Fridkin SK, Gaynes R, McGowan JE. Practice to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America. Infect. Control Hosp. Epidemiol. 21, 256-259 (2000).
3. Sunenshine RH, Liedtke LA, Jernigan DB, Strausbaugh LJ. Role of infectious disease consultants in management of antimicrobial use in hospitals. Clin. Infect. Dis 38, 934-938 (2004). (Pubitemid 38457199)
4. Dennesen PJW, van der Ven AJ, Kessels AGH, Ramsey G, Bonten MJM. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 163(6), 1371-1375 (2001). (Pubitemid 32506601)
5. Brunton S. Treating community-acquired bacterial respiratory tract infections: update on etiology, diagnosis, and antimicrobial therapy. J. Fam. Pract. 54(4), 357-364 (2005).
6. File TM, Schentag JJ. What can we learn from the time course of untreated and partially treated community-onset streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia. Clin. Infect. Dis 47(Suppl. 3), S157-S165 (2008).
7. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Feagan BG. Predictors of symptom resolution in patients with community-acquired pneumonia. Clin. Infect. Dis 31(6), 1362-1367 (2000).
8. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J. Antimicrob. Chemother. 61(2), 436-441 (2008).
9. Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. Crit. Care Clin. 25(4), 733-751 (2009).
10. Lodise TP, Drusano GL. Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit. Care Clin. 27(1), 1-18 (2011).
11. Chuang-Stein C, Beltangady M, Dunne M, Morrison B. The ethics of non-inferiority trials. Lancet 371(9616), 895-896 (2008). (Pubitemid 351375267)
12. Schentag JJ. Antibiotic dosing-does one size fit all? JAMA 279(2), 159-160 (1998). (Pubitemid 28068309)
13. Warren DK, Hill HA, Merz LR et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit. Care Med. 32(12), 2450-2456 (2004). (Pubitemid 39648227)
14. Shlaes DM, Gerding DN, John JF et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis 25(3), 584-599 (1997). (Pubitemid 127774277)
15. Rahal JJ, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial klebsiella. JAMA 280(14), 1233-1237 (1998). (Pubitemid 28469228)
16. Tillotson GS, Blondeau JM, Carroll J. Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting? Exp. Rev. Anti Infect. Ther. 5(1), 53-59 (2007). (Pubitemid 46605098)
17. van der Eerden MM, Vlaspolder F, de Graaff CS et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 60(8), 672-678 (2005). (Pubitemid 41129066)
18. Montravers P, Gauzit R, Muller C et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis 23(3), 486-494 (1996). (Pubitemid 26304496)
19. Dokouhaki P, Blondeau JM. Advances in laboratory diagnostic technologies in clinical microbiology and what this means for clinical practice. Clin. Pract. 9(4), 347-352 (2012).
20. Nilsen E. Automated identification and susceptibility determination directly from blood cultures facilitates early targeted antibiotic therapy. Scand. J. Infect. Dis 44(11), 860-865 (2012).